Ali A. Bukhari
Expertise in
5
conditions

Dr. Ali A. Bukhari

Hematology Oncology
509 Idlewild Avenue, 
Easton, MD 
Accepting New Patients
Offers Telehealth
Expertise in
5
conditions
509 Idlewild Avenue, 
Easton, MD 

Overview

Ali Bukhari is a Hematologist Oncology provider practicing medicine in Easton, Maryland.

Dr. Bukhari is highly rated in 5 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Triple-Negative Breast Cancer, Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, and Bone Marrow Transplant.

Dr. Bukhari is board certified in ABIM - Hematology - Hematology, 2020, American Board Of Internal Medicine - Internal Medicine, 2016, and ABIM - Medical Oncology - Medical Oncology, 2020. He is actively involved in clinical research, co-authoring 24 peer reviewed articles and participating in 4 clinical trials. Dr. Bukhari is currently accepting new patients.

Specialties

Hematology Oncology

Licenses

Internal Medicine in MD

Board Certifications

ABIM - Hematology - Hematology, 2020
American Board Of Internal Medicine - Internal Medicine, 2016
ABIM - Medical Oncology - Medical Oncology, 2020

Fellowships

University of Maryland Medical Center - Hematology/Oncology, 2020

Hospital Affiliations

UM Shore Regional Health - Dorchester/Easton
UM Baltimore Washington Medical Center
University Of MD Shore Medical Center At Easton
University Of MD Baltimore Washington Medical Center
University Of MD Shore Medical Ctr At Chestertown
Luminis Health Anne Arundel Medical Center, Inc

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Cancer Center at UM Shore Regional Heath
509 Idlewild Avenue, Easton, MD 21601

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Other, Drug
Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine
Study Phase: Phase 2/Phase 3
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
View 3 Less Clinical Trials

24 Total Publications

Spontaneous intradural extramedullary hematoma after mild exercise in Von Willebrand disease: A rare clinical presentation and literature review.
Spontaneous intradural extramedullary hematoma after mild exercise in Von Willebrand disease: A rare clinical presentation and literature review.
Journal: Surgical neurology international
Published: December 08, 2025
Similar Doctors
Expertise in
32
conditions
Dr. Maria R. Baer
Hematology Oncology | Oncology
Expertise in
32
conditions
Dr. Maria R. Baer
Hematology Oncology | Oncology
Referral may be required

Stoler Outpatient Cancer Clinic

22 South Greene Street, Floor 1, 
Baltimore, MD 
 (44.9 miles away)
410-328-7609
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Maria Baer is a Hematologist Oncology specialist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Baer is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Splenectomy. Dr. Baer is board certified in American Board Of Internal Medicine - Hematology, 1984 and American Board Of Internal Medicine - Internal Medicine, 1983. Dr. Baer is currently accepting new patients.

Expertise in
28
conditions
Dr. Aaron P. Rapoport
Hematology Oncology | Oncology
Expertise in
28
conditions
Dr. Aaron P. Rapoport
Hematology Oncology | Oncology
Referral may be required

Stoler Outpatient Cancer Clinic

22 South Greene Street, Floor 1, 
Baltimore, MD 
 (44.9 miles away)
410-328-7609
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aaron Rapoport is a Hematologist Oncology specialist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Rapoport is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Rapoport is board certified in American Board Of Internal Medicine - Internal Medicine, 1989 and American Board Of Internal Medicine - Hematology, 1992. Dr. Rapoport is currently accepting new patients.

Expertise in
29
conditions
Dr. Carol K. Tweed
Hematology Oncology
Expertise in
29
conditions
Dr. Carol K. Tweed
Hematology Oncology
Referral may be required

Cancer Center At UM Shore Regional Heath

509 Idlewild Avenue, 
Easton, MD 
 (0.1 miles away)
410-820-6800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carol Tweed is a Hematologist Oncology provider practicing medicine in Easton, Maryland. Dr. Tweed is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Li-Fraumeni Syndrome. Dr. Tweed is board certified in ABIM - Medical Oncology - Medical Oncology, 2008 and ABIM - Hematology - Hematology, 2013. Dr. Tweed is currently accepting new patients.

Frequently Asked Questions about Dr. Ali A. Bukhari

How do I make an appointment with Dr. Ali A. Bukhari?

You can book an appointment with Dr. Ali A. Bukhari by calling their office at 410-820-6800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ali A. Bukhari a top-rated expert for B-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ali A. Bukhari is classified as an Advanced expert for B-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ali A. Bukhari specialize in?

While Dr. Ali A. Bukhari is a Hematology Oncology, they have specific expertise in B-Cell Lymphoma, Triple-Negative Breast Cancer, and Iron Deficiency Anemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Ali A. Bukhari participate in research or clinical trials?

Yes. Dr. Ali A. Bukhari has published 24 articles and abstracts on conditions like B-Cell Lymphoma. You can view a list of Dr. Ali A. Bukhari's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ali A. Bukhari accept my insurance?

Dr. Ali A. Bukhari accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 410-820-6800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bukhari's expertise for a condition
ConditionClose
      View All 91 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile